[96a5a0]: / output / allTrials / identified / NCT03308682_identified.json

Download this file

359 lines (359 with data), 16.5 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
{
"info": {
"nct_id": "NCT03308682",
"official_title": "Safety and Dosimetry of a Long-lasting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients With Advanced Metastatic Neuroendocrine Tumors",
"inclusion_criteria": "* Adults who had neuroendocrine tumors and had metastasized, that were with histologically confirmed, inoperable and had showed disease progression according to Response Evaluation Criteria in Solid Tumors [RECIST]. Tumors were with well-differentiated histologic features and a Ki67 index of 0 to 20%. Target tumors were selected from CT, MRI, and 68Ga-DOTA-TATE PET/CT, with confirmed somatostatin receptor-expressing and at least one lesion has higher uptake than that of normal liver parenchyma on 68Ga-DOTA-TATE PET imaging within 1 weeks.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
"exclusion_criteria": "* The exclusion criteria were a serum creatinine level of more than 150 μmol per liter, baseline measured GFR of less than 50 mL/min/1.73 m2, determined by 99mTc-DTPA renal function examination, a hemoglobin level of less than 8.0 g/dl, a white-cell count of less than 2.0× 109/L, a platelet count of less than 75 × 109/L, a total bilirubin level of more than 3 times the upper limit of the normal range and a serum albumin level of more than 3.0 g per deciliter, cardiac insufficiency including carcinoid heart valve disease, a severe allergy or hypersensitivity to radiographic contrast material, claustrophobia, and pregnancy or breastfeeding.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Adults who had neuroendocrine tumors and had metastasized, that were with histologically confirmed, inoperable and had showed disease progression according to Response Evaluation Criteria in Solid Tumors [RECIST]. Tumors were with well-differentiated histologic features and a Ki67 index of 0 to 20%. Target tumors were selected from CT, MRI, and 68Ga-DOTA-TATE PET/CT, with confirmed somatostatin receptor-expressing and at least one lesion has higher uptake than that of normal liver parenchyma on 68Ga-DOTA-TATE PET imaging within 1 weeks.",
"criterions": [
{
"exact_snippets": "Adults",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
}
]
}
}
]
},
{
"exact_snippets": "neuroendocrine tumors",
"criterion": "neuroendocrine tumors",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "had metastasized",
"criterion": "metastasis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "histologically confirmed",
"criterion": "histological confirmation",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": true
}
]
},
{
"exact_snippets": "inoperable",
"criterion": "operability",
"requirements": [
{
"requirement_type": "operability",
"expected_value": false
}
]
},
{
"exact_snippets": "disease progression according to Response Evaluation Criteria in Solid Tumors [RECIST]",
"criterion": "disease progression",
"requirements": [
{
"requirement_type": "progression",
"expected_value": "RECIST criteria"
}
]
},
{
"exact_snippets": "well-differentiated histologic features",
"criterion": "histologic differentiation",
"requirements": [
{
"requirement_type": "differentiation",
"expected_value": "well-differentiated"
}
]
},
{
"exact_snippets": "Ki67 index of 0 to 20%",
"criterion": "Ki67 index",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "%"
},
{
"operator": "<=",
"value": 20,
"unit": "%"
}
]
}
}
]
},
{
"exact_snippets": "Target tumors were selected from CT, MRI, and 68Ga-DOTA-TATE PET/CT",
"criterion": "imaging modality",
"requirements": [
{
"requirement_type": "modality",
"expected_value": [
"CT",
"MRI",
"68Ga-DOTA-TATE PET/CT"
]
}
]
},
{
"exact_snippets": "confirmed somatostatin receptor-expressing",
"criterion": "somatostatin receptor expression",
"requirements": [
{
"requirement_type": "expression",
"expected_value": true
}
]
},
{
"exact_snippets": "at least one lesion has higher uptake than that of normal liver parenchyma on 68Ga-DOTA-TATE PET imaging",
"criterion": "lesion uptake",
"requirements": [
{
"requirement_type": "uptake",
"expected_value": "higher than normal liver parenchyma"
}
]
},
{
"exact_snippets": "within 1 weeks",
"criterion": "imaging timeframe",
"requirements": [
{
"requirement_type": "timeframe",
"expected_value": "within 1 week"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 70 Years",
"criterions": [
{
"exact_snippets": "maximum age of 70 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 70,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* The exclusion criteria were a serum creatinine level of more than 150 μmol per liter, baseline measured GFR of less than 50 mL/min/1.73 m2, determined by 99mTc-DTPA renal function examination, a hemoglobin level of less than 8.0 g/dl, a white-cell count of less than 2.0× 109/L, a platelet count of less than 75 × 109/L, a total bilirubin level of more than 3 times the upper limit of the normal range and a serum albumin level of more than 3.0 g per deciliter, cardiac insufficiency including carcinoid heart valve disease, a severe allergy or hypersensitivity to radiographic contrast material, claustrophobia, and pregnancy or breastfeeding.",
"criterions": [
{
"exact_snippets": "serum creatinine level of more than 150 μmol per liter",
"criterion": "serum creatinine level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 150,
"unit": "μmol per liter"
}
}
]
},
{
"exact_snippets": "baseline measured GFR of less than 50 mL/min/1.73 m2",
"criterion": "baseline measured GFR",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 50,
"unit": "mL/min/1.73 m2"
}
}
]
},
{
"exact_snippets": "hemoglobin level of less than 8.0 g/dl",
"criterion": "hemoglobin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 8.0,
"unit": "g/dl"
}
}
]
},
{
"exact_snippets": "white-cell count of less than 2.0× 109/L",
"criterion": "white-cell count",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": "<",
"value": 2.0,
"unit": "× 109/L"
}
}
]
},
{
"exact_snippets": "platelet count of less than 75 × 109/L",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": "<",
"value": 75,
"unit": "× 109/L"
}
}
]
},
{
"exact_snippets": "total bilirubin level of more than 3 times the upper limit of the normal range",
"criterion": "total bilirubin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": "more than 3 times the upper limit of the normal range"
}
]
},
{
"exact_snippets": "serum albumin level of more than 3.0 g per deciliter",
"criterion": "serum albumin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 3.0,
"unit": "g per deciliter"
}
}
]
},
{
"exact_snippets": "cardiac insufficiency including carcinoid heart valve disease",
"criterion": "cardiac insufficiency",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "severe allergy or hypersensitivity to radiographic contrast material",
"criterion": "severe allergy or hypersensitivity to radiographic contrast material",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "claustrophobia",
"criterion": "claustrophobia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "pregnancy or breastfeeding",
"criterion": "pregnancy or breastfeeding",
"requirements": [
{
"requirement_type": "status",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}